Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor.
Cell-cell communication
Histones
Immunotherapy
Multiple myeloma
NK cells
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
16 10 2019
16 10 2019
Historique:
received:
08
04
2019
accepted:
12
09
2019
entrez:
18
10
2019
pubmed:
18
10
2019
medline:
4
8
2020
Statut:
epublish
Résumé
Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer activity is mediated through interaction of a wide array of activating and inhibitory receptors with their ligands on tumor cells. After activation, NK cells also secrete a variety of pro-inflammatory molecules that contribute to the final immune response by modulating other innate and adaptive immune cells. In this regard, external proteins from NK cell secretome and the mechanisms by which they mediate these responses are poorly defined. TRANS-stable-isotope labeling of amino acids in cell culture (TRANS-SILAC) combined with proteomic was undertaken to identify early materials transferred between cord blood-derived NK cells (CB-NK) and multiple myeloma (MM) cells. Further in vitro and in vivo studies with knock-down of histones and CD138, overexpression of histones and addition of exogenous histones were undertaken to confirm TRANS-SILAC results and to determine functional roles of this material transferred. We describe a novel mechanism by which histones are actively released by NK cells early after contact with MM cells. We show that extracellular histones bind to the heparan sulfate proteoglycan CD138 on the surface of MM cells to promote the creation of immune-tumor cell clusters bringing immune and MM cells into close proximity, and thus facilitating not only NK but also T lymphocyte anti-MM activity. This study demonstrates a novel immunoregulatory role of NK cells against MM cells mediated by histones, and an additional role of NK cells modulating T lymphocytes activity that will open up new avenues to design future immunotherapy clinical strategies.
Sections du résumé
BACKGROUND
Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer activity is mediated through interaction of a wide array of activating and inhibitory receptors with their ligands on tumor cells. After activation, NK cells also secrete a variety of pro-inflammatory molecules that contribute to the final immune response by modulating other innate and adaptive immune cells. In this regard, external proteins from NK cell secretome and the mechanisms by which they mediate these responses are poorly defined.
METHODS
TRANS-stable-isotope labeling of amino acids in cell culture (TRANS-SILAC) combined with proteomic was undertaken to identify early materials transferred between cord blood-derived NK cells (CB-NK) and multiple myeloma (MM) cells. Further in vitro and in vivo studies with knock-down of histones and CD138, overexpression of histones and addition of exogenous histones were undertaken to confirm TRANS-SILAC results and to determine functional roles of this material transferred.
RESULTS
We describe a novel mechanism by which histones are actively released by NK cells early after contact with MM cells. We show that extracellular histones bind to the heparan sulfate proteoglycan CD138 on the surface of MM cells to promote the creation of immune-tumor cell clusters bringing immune and MM cells into close proximity, and thus facilitating not only NK but also T lymphocyte anti-MM activity.
CONCLUSION
This study demonstrates a novel immunoregulatory role of NK cells against MM cells mediated by histones, and an additional role of NK cells modulating T lymphocytes activity that will open up new avenues to design future immunotherapy clinical strategies.
Identifiants
pubmed: 31619273
doi: 10.1186/s40425-019-0739-1
pii: 10.1186/s40425-019-0739-1
pmc: PMC6794915
doi:
Substances chimiques
Histones
0
SDC1 protein, human
0
Syndecan-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cell Death Differ. 2015 Jan;22(1):96-107
pubmed: 25168239
Sci Rep. 2017 Feb 21;7:43039
pubmed: 28220899
Br J Haematol. 2017 May;177(3):457-466
pubmed: 28295190
Peptides. 2011 Oct;32(10):2003-9
pubmed: 21930170
Cell Death Dis. 2016 Dec 8;7(12):e2518
pubmed: 27929534
Drug Discov Today. 2016 Feb;21(2):278-87
pubmed: 26456530
Blood. 2002 Feb 15;99(4):1405-10
pubmed: 11830493
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Am J Clin Pathol. 2007 Jun;127(6):881-6
pubmed: 17509985
J Biol Chem. 2009 Sep 18;284(38):26085-95
pubmed: 19596856
ACS Biomater Sci Eng. 2018 Aug 13;4(8):2922-2933
pubmed: 30533518
F1000Res. 2017 Dec 18;6:2143
pubmed: 29399324
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):null
pubmed: 21690215
Blood. 2014 Feb 13;123(7):1098-101
pubmed: 24264231
Int J Mol Sci. 2017 Aug 29;18(9):null
pubmed: 28850071
Biochim Biophys Acta. 2012 Mar;1818(3):869-76
pubmed: 22230351
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Sci Rep. 2017 Jan 11;7:40623
pubmed: 28074895
Int Immunol. 2009 May;21(5):599-606
pubmed: 19325034
Cell Death Dis. 2014 Aug 14;5:e1370
pubmed: 25118930
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Immunol Rev. 2006 Dec;214:202-18
pubmed: 17100886
Leukemia. 2018 Feb;32(2):520-531
pubmed: 28725044
Matrix Biol. 2014 Apr;35:51-5
pubmed: 24145152
J Mol Med (Berl). 2014 May;92(5):465-72
pubmed: 24706102
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
PLoS One. 2013 Oct 18;8(10):e76781
pubmed: 24204673
Front Microbiol. 2013 Oct 01;4:294
pubmed: 24101917
Immunity. 2008 Nov 14;29(5):819-33
pubmed: 19006696
Science. 2015 Jul 17;349(6245):316-20
pubmed: 26185250
Blood. 2005 Oct 1;106(7):2252-8
pubmed: 15933055
Trends Cancer. 2017 Jun;3(6):407-422
pubmed: 28718416
Cancer Lett. 2008 Nov 18;271(1):47-55
pubmed: 18617323
J Immunol Res. 2017;2017:4218254
pubmed: 28428965
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Biochim Biophys Acta. 2016 Oct;1858(10):2322-2333
pubmed: 27003126
J Exp Med. 2009 Sep 28;206(10):2235-51
pubmed: 19720840
Leukemia. 2019 Aug 22;:null
pubmed: 31439945
Trends Biochem Sci. 2003 Mar;28(3):145-51
pubmed: 12633994
Nat Methods. 2010 Nov;7(11):923-7
pubmed: 20935649
Cell. 2016 May 5;165(4):792-800
pubmed: 27153493
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982